7.50Open7.50Pre Close0 Volume1 Open Interest100.00Strike Price0.00Turnover417.83%IV60.52%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry7.50Extrinsic Value100Contract SizeAmericanOptions Type-0.0674Delta0.0007Gamma31.24Leverage Ratio-0.9480Theta-0.0073Rho-2.11Eff Leverage0.0561Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet